QIAGEN Expands AI Capabilities for Bioinformatics & Drug Discovery

The expansion includes IPA Investigator, an AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the QIAGEN Discovery Platform, which extends AI capabilities into drug discovery.

QIAGEN has introduced new artificial intelligence (AI) capabilities designed to help researchers analyze complex biological and genomic data and automate parts of drug discovery workflows.

The expansion includes IPA Investigator, an AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the QIAGEN Discovery Platform, which extends AI capabilities into drug discovery. QIAGEN Digital Insights (QDI) is developing both offerings, and its bioinformatics solutions are used by around 150,000 users.

IPA Investigator enables researchers to ask biological questions using natural language, identify relevant biological relationships, recommend analyses and conduct those analyses within IPA. Researchers can also combine their experimental data with existing biological knowledge to investigate disease mechanisms, potential drug targets and areas for further research.

QIAGEN said the tools are designed to keep the scientific evidence supporting AI-generated results visible. The approach combines AI with expert-reviewed biological, genomic and clinical information, allowing researchers to examine the basis for results rather than relying solely on automated outputs.

Researchers at the University of Bergen in Norway tested IPA Investigator using datasets containing intentionally misleading sample comparisons. According to Dr. Simona Chera, Professor at the university, the system identified the issue, warned against overinterpreting the findings, and suggested an alternative experimental design.

The QIAGEN Discovery Platform applies similar capabilities to drug discovery workflows. The platform integrates AI with QIAGEN’s biomedical knowledge base and molecular data to support the identification of potential drug targets and biomarkers, generation of research hypotheses, and automation of selected discovery processes.

QIAGEN is also expanding AI across other QDI products. This includes AI-powered translation capabilities in QIAGEN Clinical Insight (QCI) Interpret and machine learning combined with expert-reviewed information in Franklin by QIAGEN.

The company said the new capabilities build on more than 25 years of biomedical knowledge developed through QDI. The global AI in bioinformatics market is projected to grow from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence.

Stay tuned for more such updates on Digital Health News